Cargando…
Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory
OBJECTIVE: The prognostic value of cerebrospinal fluid neurofilament light chain, total tau, phosphorylated tau(181), and amyloid beta(1‐42) was examined in frontotemporal dementia subtypes. METHODS: We compared baseline biomarkers between 49 controls, 40 patients with behavioral variant frontotempo...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186942/ https://www.ncbi.nlm.nih.gov/pubmed/30349860 http://dx.doi.org/10.1002/acn3.643 |
_version_ | 1783362939267317760 |
---|---|
author | Ljubenkov, Peter A. Staffaroni, Adam M. Rojas, Julio C. Allen, Isabel E. Wang, Ping Heuer, Hilary Karydas, Anna Kornak, John Cobigo, Yann Seeley, William W. Grinberg, Lea T. Spina, Salvatore Fagan, Anne M. Jerome, Gina Knopman, David Boeve, Brad F. Dickerson, Bradford C. Kramer, Joel Miller, Bruce Boxer, Adam L. Rosen, Howard J. |
author_facet | Ljubenkov, Peter A. Staffaroni, Adam M. Rojas, Julio C. Allen, Isabel E. Wang, Ping Heuer, Hilary Karydas, Anna Kornak, John Cobigo, Yann Seeley, William W. Grinberg, Lea T. Spina, Salvatore Fagan, Anne M. Jerome, Gina Knopman, David Boeve, Brad F. Dickerson, Bradford C. Kramer, Joel Miller, Bruce Boxer, Adam L. Rosen, Howard J. |
author_sort | Ljubenkov, Peter A. |
collection | PubMed |
description | OBJECTIVE: The prognostic value of cerebrospinal fluid neurofilament light chain, total tau, phosphorylated tau(181), and amyloid beta(1‐42) was examined in frontotemporal dementia subtypes. METHODS: We compared baseline biomarkers between 49 controls, 40 patients with behavioral variant frontotemporal dementia, 24 with semantic variant primary progressive aphasia, and 26 with nonfluent variant primary progressive aphasia. Linear mixed effect models were used to assess the value of baseline biomarkers in predicting clinical and radiographic change in patient cohorts over multiple yearly follow up visits. RESULTS: Neurofilament light chain concentrations were lowest in controls. Elevated baseline neurofilament light chain predicted faster worsening in clinical severity, frontotemporal volume and frontotemporal fractional anisotropy in patients with behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. High total tau similarly predicted faster progression in nonfluent variant primary progressive aphasia. In behavioral variant frontotemporal dementia, higher phosphorylated tau(181) predicted faster clinical progression whereas lower amyloid beta(1‐42) predicted faster volumetric and fractional anisotropy reduction. Neurofilament light chain and phosphorylated tau(181) were of greater predictive value in patients with tau pathology as compared to TDP‐43 pathology. Baseline neurofilament light chain correlated with baseline clinical severity and frontotemporal volume in behavioral variant frontotemporal dementia. Baseline total tau correlated with baseline clinical severity in semantic variant primary progressive aphasia. INTERPRETATION: High cerebrospinal fluid neurofilament light chain predicts more aggressive disease in behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. Total tau, phosphorylated tau(181), and amyloid beta(1‐42) also predict some measures of disease aggressiveness in frontotemporal dementia. |
format | Online Article Text |
id | pubmed-6186942 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-61869422018-10-22 Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory Ljubenkov, Peter A. Staffaroni, Adam M. Rojas, Julio C. Allen, Isabel E. Wang, Ping Heuer, Hilary Karydas, Anna Kornak, John Cobigo, Yann Seeley, William W. Grinberg, Lea T. Spina, Salvatore Fagan, Anne M. Jerome, Gina Knopman, David Boeve, Brad F. Dickerson, Bradford C. Kramer, Joel Miller, Bruce Boxer, Adam L. Rosen, Howard J. Ann Clin Transl Neurol Research Articles OBJECTIVE: The prognostic value of cerebrospinal fluid neurofilament light chain, total tau, phosphorylated tau(181), and amyloid beta(1‐42) was examined in frontotemporal dementia subtypes. METHODS: We compared baseline biomarkers between 49 controls, 40 patients with behavioral variant frontotemporal dementia, 24 with semantic variant primary progressive aphasia, and 26 with nonfluent variant primary progressive aphasia. Linear mixed effect models were used to assess the value of baseline biomarkers in predicting clinical and radiographic change in patient cohorts over multiple yearly follow up visits. RESULTS: Neurofilament light chain concentrations were lowest in controls. Elevated baseline neurofilament light chain predicted faster worsening in clinical severity, frontotemporal volume and frontotemporal fractional anisotropy in patients with behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. High total tau similarly predicted faster progression in nonfluent variant primary progressive aphasia. In behavioral variant frontotemporal dementia, higher phosphorylated tau(181) predicted faster clinical progression whereas lower amyloid beta(1‐42) predicted faster volumetric and fractional anisotropy reduction. Neurofilament light chain and phosphorylated tau(181) were of greater predictive value in patients with tau pathology as compared to TDP‐43 pathology. Baseline neurofilament light chain correlated with baseline clinical severity and frontotemporal volume in behavioral variant frontotemporal dementia. Baseline total tau correlated with baseline clinical severity in semantic variant primary progressive aphasia. INTERPRETATION: High cerebrospinal fluid neurofilament light chain predicts more aggressive disease in behavioral variant frontotemporal dementia and nonfluent variant primary progressive aphasia. Total tau, phosphorylated tau(181), and amyloid beta(1‐42) also predict some measures of disease aggressiveness in frontotemporal dementia. John Wiley and Sons Inc. 2018-09-20 /pmc/articles/PMC6186942/ /pubmed/30349860 http://dx.doi.org/10.1002/acn3.643 Text en © 2018 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Research Articles Ljubenkov, Peter A. Staffaroni, Adam M. Rojas, Julio C. Allen, Isabel E. Wang, Ping Heuer, Hilary Karydas, Anna Kornak, John Cobigo, Yann Seeley, William W. Grinberg, Lea T. Spina, Salvatore Fagan, Anne M. Jerome, Gina Knopman, David Boeve, Brad F. Dickerson, Bradford C. Kramer, Joel Miller, Bruce Boxer, Adam L. Rosen, Howard J. Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory |
title | Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory |
title_full | Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory |
title_fullStr | Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory |
title_full_unstemmed | Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory |
title_short | Cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory |
title_sort | cerebrospinal fluid biomarkers predict frontotemporal dementia trajectory |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6186942/ https://www.ncbi.nlm.nih.gov/pubmed/30349860 http://dx.doi.org/10.1002/acn3.643 |
work_keys_str_mv | AT ljubenkovpetera cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT staffaroniadamm cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT rojasjulioc cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT allenisabele cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT wangping cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT heuerhilary cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT karydasanna cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT kornakjohn cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT cobigoyann cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT seeleywilliamw cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT grinbergleat cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT spinasalvatore cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT faganannem cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT jeromegina cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT knopmandavid cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT boevebradf cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT dickersonbradfordc cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT kramerjoel cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT millerbruce cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT boxeradaml cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory AT rosenhowardj cerebrospinalfluidbiomarkerspredictfrontotemporaldementiatrajectory |